CESC Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 6:02 am

Competitors of CESC Ltd

All Competitor Stocks of CESC Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:45 pm

Below is a detailed analysis of the quarterly data for CESC Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 5,202.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,877.00 Cr. (Mar 2025) to 5,202.00 Cr., marking an increase of 1,325.00 Cr..
• For Expenses, as of Jun 2025, the value is 4,338.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,065.00 Cr. (Mar 2025) to 4,338.00 Cr., marking an increase of 1,273.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 864.00 Cr.. The value appears strong and on an upward trend. It has increased from 812.00 Cr. (Mar 2025) to 864.00 Cr., marking an increase of 52.00 Cr..
• For OPM %, as of Jun 2025, the value is 17.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 17.00%, marking a decrease of 4.00%.
• For Other Income, as of Jun 2025, the value is 311.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Mar 2025) to 311.00 Cr., marking an increase of 18.00 Cr..
• For Interest, as of Jun 2025, the value is 363.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 335.00 Cr. (Mar 2025) to 363.00 Cr., marking an increase of 28.00 Cr..
• For Depreciation, as of Jun 2025, the value is 304.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 304.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 508.00 Cr.. The value appears strong and on an upward trend. It has increased from 466.00 Cr. (Mar 2025) to 508.00 Cr., marking an increase of 42.00 Cr..
• For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Mar 2025) to 20.00%, marking an increase of 3.00%.
• For Net Profit, as of Jun 2025, the value is 404.00 Cr.. The value appears strong and on an upward trend. It has increased from 385.00 Cr. (Mar 2025) to 404.00 Cr., marking an increase of 19.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.92. The value appears strong and on an upward trend. It has increased from 2.81 (Mar 2025) to 2.92, marking an increase of 0.11.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:33 pm

Growth

Last Updated: September 5, 2025, 1:50 am

Balance Sheet

Last Updated: September 10, 2025, 1:38 pm

Below is a detailed analysis of the balance sheet data for CESC Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 133.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 133.00 Cr..
• For Reserves, as of Mar 2025, the value is 11,876.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,312.00 Cr. (Mar 2024) to 11,876.00 Cr., marking an increase of 564.00 Cr..
• For Borrowings, as of Mar 2025, the value is 17,978.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 14,544.00 Cr. (Mar 2024) to 17,978.00 Cr., marking an increase of 3,434.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 10,994.00 Cr.. The value appears to be improving (decreasing). It has decreased from 11,179.00 Cr. (Mar 2024) to 10,994.00 Cr., marking a decrease of 185.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 40,981.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37,168.00 Cr. (Mar 2024) to 40,981.00 Cr., marking an increase of 3,813.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 22,766.00 Cr.. The value appears strong and on an upward trend. It has increased from 22,131.00 Cr. (Mar 2024) to 22,766.00 Cr., marking an increase of 635.00 Cr..
• For CWIP, as of Mar 2025, the value is 427.00 Cr.. The value appears strong and on an upward trend. It has increased from 175.00 Cr. (Mar 2024) to 427.00 Cr., marking an increase of 252.00 Cr..
• For Investments, as of Mar 2025, the value is 59.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to 59.00 Cr., marking an increase of 2.00 Cr..
• For Other Assets, as of Mar 2025, the value is 17,728.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,806.00 Cr. (Mar 2024) to 17,728.00 Cr., marking an increase of 2,922.00 Cr..
• For Total Assets, as of Mar 2025, the value is 40,981.00 Cr.. The value appears strong and on an upward trend. It has increased from 37,168.00 Cr. (Mar 2024) to 40,981.00 Cr., marking an increase of 3,813.00 Cr..

However, the Borrowings (17,978.00 Cr.) are higher than the Reserves (11,876.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for CESC Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 10.38 (Mar 24) to 10.32, marking a decrease of 0.06.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 10.38 (Mar 24) to 10.32, marking a decrease of 0.06.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.77. This value is within the healthy range. It has decreased from 20.00 (Mar 24) to 19.77, marking a decrease of 0.23.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 90.15. It has increased from 85.92 (Mar 24) to 90.15, marking an increase of 4.23.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 90.15. It has increased from 85.92 (Mar 24) to 90.15, marking an increase of 4.23.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 127.62. It has increased from 114.80 (Mar 24) to 127.62, marking an increase of 12.82.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 23.00. This value is within the healthy range. It has increased from 17.84 (Mar 24) to 23.00, marking an increase of 5.16.
• For PBIT / Share (Rs.), as of Mar 25, the value is 13.95. This value is within the healthy range. It has increased from 8.71 (Mar 24) to 13.95, marking an increase of 5.24.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.38. This value is within the healthy range. It has increased from 12.63 (Mar 24) to 13.38, marking an increase of 0.75.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.72. This value is within the healthy range. It has decreased from 10.86 (Mar 24) to 10.72, marking a decrease of 0.14.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.28. This value is within the healthy range. It has decreased from 10.33 (Mar 24) to 10.28, marking a decrease of 0.05.
• For PBDIT Margin (%), as of Mar 25, the value is 18.02. This value is within the healthy range. It has increased from 15.53 (Mar 24) to 18.02, marking an increase of 2.49.
• For PBIT Margin (%), as of Mar 25, the value is 10.93. This value is within the healthy range. It has increased from 7.58 (Mar 24) to 10.93, marking an increase of 3.35.
• For PBT Margin (%), as of Mar 25, the value is 10.48. This value is within the healthy range. It has decreased from 11.00 (Mar 24) to 10.48, marking a decrease of 0.52.
• For Net Profit Margin (%), as of Mar 25, the value is 8.39. This value is within the healthy range. It has decreased from 9.46 (Mar 24) to 8.39, marking a decrease of 1.07.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.05. This value is within the healthy range. It has decreased from 8.99 (Mar 24) to 8.05, marking a decrease of 0.94.
• For Return on Networth / Equity (%), as of Mar 25, the value is 11.39. This value is below the healthy minimum of 15. It has decreased from 12.02 (Mar 24) to 11.39, marking a decrease of 0.63.
• For Return on Capital Employeed (%), as of Mar 25, the value is 5.71. This value is below the healthy minimum of 10. It has increased from 3.83 (Mar 24) to 5.71, marking an increase of 1.88.
• For Return On Assets (%), as of Mar 25, the value is 3.34. This value is below the healthy minimum of 5. It has decreased from 3.70 (Mar 24) to 3.34, marking a decrease of 0.36.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 1.07. This value exceeds the healthy maximum of 1. It has decreased from 1.14 (Mar 24) to 1.07, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 1.48. This value exceeds the healthy maximum of 1. It has increased from 1.44 (Mar 24) to 1.48, marking an increase of 0.04.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has increased from 0.40 (Mar 24) to 0.43, marking an increase of 0.03.
• For Current Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.90, marking a decrease of 0.13.
• For Quick Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 1.91 (Mar 24) to 1.81, marking a decrease of 0.10.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 21.20. This value exceeds the healthy maximum of 8. It has increased from 17.39 (Mar 24) to 21.20, marking an increase of 3.81.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 43.57. This value is within the healthy range. It has increased from 43.33 (Mar 24) to 43.57, marking an increase of 0.24.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 23.17. This value is within the healthy range. It has increased from 23.00 (Mar 24) to 23.17, marking an increase of 0.17.
• For Earning Retention Ratio (%), as of Mar 25, the value is 56.43. This value is within the healthy range. It has decreased from 56.67 (Mar 24) to 56.43, marking a decrease of 0.24.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 76.83. This value exceeds the healthy maximum of 70. It has decreased from 77.00 (Mar 24) to 76.83, marking a decrease of 0.17.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.31. This value is below the healthy minimum of 3. It has increased from 1.93 (Mar 24) to 2.31, marking an increase of 0.38.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 3. It has increased from 0.74 (Mar 24) to 1.14, marking an increase of 0.40.
• For Enterprise Value (Cr.), as of Mar 25, the value is 34,759.15. It has increased from 30,521.81 (Mar 24) to 34,759.15, marking an increase of 4,237.34.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.04. This value is within the healthy range. It has increased from 2.00 (Mar 24) to 2.04, marking an increase of 0.04.
• For EV / EBITDA (X), as of Mar 25, the value is 11.35. This value is within the healthy range. It has decreased from 12.84 (Mar 24) to 11.35, marking a decrease of 1.49.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.21. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.21, marking an increase of 0.15.
• For Retention Ratios (%), as of Mar 25, the value is 56.42. This value is within the healthy range. It has decreased from 56.66 (Mar 24) to 56.42, marking a decrease of 0.24.
• For Price / BV (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.41 (Mar 24) to 1.71, marking an increase of 0.30.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.21. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.21, marking an increase of 0.15.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.08 (Mar 24) to 0.06, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness